Omega-3 (Fish Oil)
Omega-3 fatty acids (EPA and DHA) have strong, consistent evidence for lowering fasting triglycerides, an effect recognized by the FDA through prescription-drug approvals for fish oil at 4 g/day. The cardiovascular picture is more complicated: pharmaceutical-grade pure EPA at 4 g/day in high-risk statin-treated patients reduced major cardiac events by 25% in the REDUCE-IT trial (PMID 30415628), but standard-dose supplementation (1 g/day) did not reduce cardiovascular events in the large VITAL primary-prevention trial (PMID 30415637), and the difference in dose, formulation, and patient population matters enormously. Cognition claims are not supported by randomized trial evidence in cognitively healthy adults (Cochrane review, PMID 22696350), while DHA is a structural requirement for fetal brain development with limited but suggestive evidence supporting supplementation during pregnancy.
Generally well tolerated at 1-3 g EPA+DHA/day; most common side effects are mild GI issues (fishy burps, loose stools) that are reduced by taking with food or using enteric-coated products. Meta-analyses document a dose-dependent atrial fibrillation signal at intakes above 1,500 mg EPA+DHA/day in high-cardiovascular-risk populations; individuals with pre-existing AF or high AF risk should discuss high-dose supplementation with a clinician before starting. At doses of 3 g/day or higher, omega-3 may have mild antiplatelet effects; people on anticoagulants or scheduled for surgery should consult a clinician. Not a treatment for any disease.
Full safety details belowEvidence by use
Each use graded independently. A strong grade for one use does not carry over to others.
Strong, consistent human trials.
Emerging and mixed. Not settled.
Moderate evidence; some gaps remain.
Preclinical or weak. Not established in people.
Generally well tolerated at 1-3 g EPA+DHA/day; most common side effects are mild GI issues (fishy burps, loose stools) that are reduced by taking with food or using enteric-coated products. Meta-analyses document a dose-dependent atrial fibrillation signal at intakes above 1,500 mg EPA+DHA/day in high-cardiovascular-risk populations; individuals with pre-existing AF or high AF risk should discuss high-dose supplementation with a clinician before starting. At doses of 3 g/day or higher, omega-3 may have mild antiplatelet effects; people on anticoagulants or scheduled for surgery should consult a clinician. Not a treatment for any disease.
Who takes it and why
Each expert's dose and stated reason, linked to their own words. Attribution only; no endorsement implied.
Photo: Jamesbrianbounds, CC BY-SA 4.0, via Wikimedia Commons ↗EPA reduces inflammatory cytokines that divert tryptophan away from serotonin synthesis; cites a double-blind study finding 1,000 mg/day EPA equivalent to 20 mg fluoxetine for depressive symptoms, with synergistic effect when combined; personally states: 'I personally take 1000 milligrams of EPA per day... I notice a pretty substantial positive effect'
www.hubermanlab.com ↗Attribution only; no endorsement implied.
Photo: Jop van Velthuis, CC BY-SA 4.0, via Wikimedia Commons ↗States this is a superior product; had independent toxicology analytics conducted to confirm absence of lead, arsenic, mercury, and other contaminants; presents as part of his documented personal supplement stack
peterattiamd.com ↗Attribution only; no endorsement implied.
Emphasizes Omega-3 Index as the relevant biomarker; cites evidence that >= 8% Omega-3 Index is associated with approximately 5 years greater life expectancy vs <= 4%; frames mechanism as resolution of inflammation through specialized pro-resolving mediators (SPMs); recommends testing Omega-3 Index rather than assuming a fixed dose
www.foundmyfitness.com ↗Attribution only; no endorsement implied.
Photo: M Robertson, CC BY 4.0, via Wikimedia Commons ↗Uses algae-sourced omega-3 to avoid ocean contaminants and fish; emphasizes brain health (DHA as structural brain fat), heart health (blood pressure, vascular function, cholesterol support), and joint/inflammatory function; lower dose vs Attia/Patrick consistent with systematic risk/benefit optimization approach
blueprint.bryanjohnson.com ↗Attribution only; no endorsement implied.
Recommends the lower end of the dose range, citing AHA guidance (250-500 mg/day) and concern about dose-dependent atrial fibrillation risk at >1,500 mg/day in high-CV-risk populations; notes VITAL (840 mg/day) did not show an AF risk signal and explicitly avoids megadosing
drstanfield.com ↗Attribution only; no endorsement implied.
Which Omega-3 (Fish Oil) should you buy?
The short version: plain omega-3 (fish oil) is the most-studied and least-expensive form, and any product that is third-party certified is a safe bet. Certification (NSF Certified for Sport or USP Verified) screens for banned substances and confirms the label matches what is in the bottle. Here are recognizable brands that carry it. We do not certify products and take no payment to list them.
35 Omega-3 (Fish Oil) products are third-party certified in total. See the full list →
Published lab tests on Omega-3 (Fish Oil)
These studies test the ingredient category, not a single branded product. All attributed to their original source. We do not run the tests.
83% of tested products exceeded international peroxide value limits; 50% exceeded TOTOX limits; only 8% met all three oxidation standards. 69% contained less than 67% of labeled EPA+DHA.
50% of products exceeded voluntary recommended levels for at least one oxidation marker; 41% had anisidine values above 20; 39% had TOTOX above 26. Replicates Albert et al. across a larger North American product set.
Sources
- Fish oil supplements in New Zealand are highly oxidised and do not meet label content of n-3 PUFA (2015) observational
- Oxidation levels of North American over-the-counter n-3 (omega-3) supplements and the influence of supplement formulation and delivery form on evaluating oxidative safety (2015) observational
- Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia (2019) rct
- Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer (2019) rct
- Effect of omega-3 fatty acids on cardiovascular outcomes: A systematic review and meta-analysis (2021) review
- Omega-3 Fatty Acid Dietary Supplements Consumed During Pregnancy and Lactation and Child Neurodevelopment: A Systematic Review (2021) review
- A Randomized Trial of Prenatal n-3 Fatty Acid Supplementation and Preterm Delivery (2019) rct
- Omega 3 fatty acid for the prevention of cognitive decline and dementia (2012) review